You are here: Industry Insights > VIR-7831

News List

UAE approves highly effective new treatment for COVID-19 firstwordpharma
May 31, 2021
The Ministry of Health and Prevention (MoHAP) has approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to both license and enable immediate patient use.
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19 worldpharmanews
April 16, 2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and ...
GSK and Vir seek EUA for monoclonal antibody to treat Covid-19 pharmaceutical-technology
March 30, 2021
GlaxoSmithKline (GSK) and Vir Biotechnology have applied to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) for SARS-CoV-2 monoclonal antibody VIR-7831 (GSK4182136) to treat Covid-19.
Lilly, Vir and GSK report positive data from Covid-19 antibody trial pharmaceutical-technology
March 30, 2021
Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline (GSK) have reported topline data from the expanded Phase II BLAZE-4 trial of bamlanivimab (LY-CoV555) co-administered with VIR-7831 (GSK4182136) in low-risk adult patients with mild to ...
Vir, GSK to seek EUA for COVID-19 antibody therapy expresspharma
March 12, 2021
Vir and GSK also said that a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African and Brazilian variants of the coronavirus.
US closes enrolment in two COVID-19 antibody studies due to futility europeanpharmaceuticalreview
March 08, 2021
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19 worldpharmanews
December 21, 2020
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 ...